137 related articles for article (PubMed ID: 36748193)
1. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
2. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma.
Ong JR; Bamodu OA; Khang NV; Lin YK; Yeh CT; Lee WH; Cherng YG
Cells; 2021 Jan; 10(1):. PubMed ID: 33477333
[TBL] [Abstract][Full Text] [Related]
3. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
4. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways.
Yang Y; Liang Z; Xia Z; Wang X; Ma Y; Sheng Z; Gu Q; Shen G; Zhou L; Zhu H; Xu N; Liang S
Cell Commun Signal; 2019 Jul; 17(1):82. PubMed ID: 31345225
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation.
Liu Y; Wang X; Zeng X; Wu Y; Liu X; Tan J; Li X
Open Med (Wars); 2022; 17(1):1183-1202. PubMed ID: 35859792
[TBL] [Abstract][Full Text] [Related]
6. SUMO pathway components as possible cancer biomarkers.
Mattoscio D; Chiocca S
Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
[TBL] [Abstract][Full Text] [Related]
7. Increased SUMO-activating enzyme SAE1/UBA2 promotes glycolysis and pathogenic behavior of rheumatoid fibroblast-like synoviocytes.
Wang C; Xiao Y; Lao M; Wang J; Xu S; Li R; Xu X; Kuang Y; Shi M; Zou Y; Wang Q; Liang L; Zheng SG; Xu H
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32938830
[TBL] [Abstract][Full Text] [Related]
8. A fine-tuning mechanism underlying self-control for autophagy: deSUMOylation of BECN1 by SENP3.
Liu K; Guo C; Lao Y; Yang J; Chen F; Zhao Y; Yang Y; Yang J; Yi J
Autophagy; 2020 Jun; 16(6):975-990. PubMed ID: 31373534
[TBL] [Abstract][Full Text] [Related]
9. Diversification of SUMO-activating enzyme in Arabidopsis: implications in SUMO conjugation.
Castaño-Miquel L; Seguí J; Manrique S; Teixeira I; Carretero-Paulet L; Atencio F; Lois LM
Mol Plant; 2013 Sep; 6(5):1646-60. PubMed ID: 23482370
[TBL] [Abstract][Full Text] [Related]
10. PAPILLARY THYROID CANCER IS CHARACTERIZED BY ALTERED EXPRESSION OF GENES INVOLVED IN THE SUMOYLATION PROCESS.
Tuccilli C; Baldini E; Sorrenti S; Di Gioia C; Bosco D; Ascoli V; Mian C; Barollo S; Rendina R; Coccaro C; Pepe M; Catania A; Bononi M; Tartaglia F; De Antoni E; D'Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2015; 29(3):655-62. PubMed ID: 26403403
[TBL] [Abstract][Full Text] [Related]
11. SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma.
Qin Y; Bao H; Pan Y; Yin M; Liu Y; Wu S; Li H
Mol Med Rep; 2014 Mar; 9(3):877-81. PubMed ID: 24399357
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of Sumoylation Enzymes SAE1, U BA2, UBC9, PIAS1 and RanBP2 in Major Ocular Tissues of Mouse Eye.
Nie Q; Yang L; Qing W; Xie J; Gong X; Chen H; Gan Y; Wang L; Xiang JW; Xiao Y; Chen Z; Li DW
Curr Mol Med; 2018; 18(6):376-382. PubMed ID: 30479214
[TBL] [Abstract][Full Text] [Related]
13. Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K; Park H; Pandey N; Azuma Y; De Guzman RN
J Biol Chem; 2017 Jun; 292(24):10230-10238. PubMed ID: 28455449
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.
Wang H; Yang T; Wu J; Chen D; Wang W
Transplant Proc; 2023 May; 55(4):945-951. PubMed ID: 37236867
[TBL] [Abstract][Full Text] [Related]
15. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
16. SUMOylation of RNF146 results in Axin degradation and activation of Wnt/β-catenin signaling to promote the progression of hepatocellular carcinoma.
Li W; Han Q; Zhu Y; Zhou Y; Zhang J; Wu W; Li Y; Liu L; Qiu Y; Hu K; Yin D
Oncogene; 2023 May; 42(21):1728-1740. PubMed ID: 37029301
[TBL] [Abstract][Full Text] [Related]
17. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
18. ROS-mediated up-regulation of SAE1 by Helicobacter pylori promotes human gastric tumor genesis and progression.
Shi L; Shangguan J; Lu Y; Rong J; Yang Q; Yang Y; Xie C; Shu X
J Transl Med; 2024 Feb; 22(1):148. PubMed ID: 38351014
[TBL] [Abstract][Full Text] [Related]
19. The SUMO-specific protease SENP2 plays an essential role in the regulation of Kv7.2 and Kv7.3 potassium channels.
Chen X; Zhang Y; Ren X; Su Q; Liu Y; Dang X; Qin Y; Yang X; Xing Z; Shen Y; Wang Y; Bai Z; Yeh ETH; Wu H; Qi Y
J Biol Chem; 2021 Oct; 297(4):101183. PubMed ID: 34509475
[TBL] [Abstract][Full Text] [Related]
20. Versatile recombinant SUMOylation system for the production of SUMO-modified protein.
Weber AR; Schuermann D; Schär P
PLoS One; 2014; 9(7):e102157. PubMed ID: 25007328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
